MetLife Q2 2026 Earnings Call Summary

1Key Financial Results and Metrics

Adjusted Earnings: Approximately $1.6 billion, or $2.43 per share, a 15% increase year-over-year.

Adjusted EPS Growth: Up 20%, reflecting disciplined capital management.

Adjusted Premiums, Fees, and Revenues: Increased by 5% year-over-year, excluding pension risk transfers.

Sales Growth: Rose 7%, driven by strong international performance.

Variable Investment Income: Totaled $231 million pretax, higher than the prior year.

Adjusted Return on Equity (ROE): 17%, at the top end of the 15%-17% target range.

Direct Expense Ratio: 12.1%, consistent with full-year targets despite the integration of PineBridge Investments.

2Strategic Updates and Business Highlights

New Frontier Strategy: MetLife's strategy focuses on two earnings engines—capital light (Group Benefits, Latin America, EMEA, Asset Management) and capital driven (Retirement and Spread-based businesses)—which are performing well and supporting growth.

Group Benefits: Adjusted earnings of $503 million, up 25% year-over-year, with a favorable Group Life mortality ratio of 79%.

Retirement and Income Solutions (RIS): Adjusted earnings of $377 million, up 2%, with a 19% increase in adjusted PFOs, driven by U.K. longevity reinsurance.

Asia Performance: Adjusted earnings of $420 million, a 21% increase, with sales up 17% on a constant currency basis.

Latin America: Adjusted earnings of $268 million, a record high, up 15% year-over-year.

MetLife Investment Management (MIM): Adjusted earnings of $57 million, up 6%, with total assets under management reaching approximately $748 billion.

3Forward Guidance and Outlook

Share Repurchase: Announced a new $3 billion share repurchase authorization, reflecting confidence in capital generation.

Capital Deployment: Focused on funding organic growth and pursuing strategic inorganic investments, particularly in asset management and group segments.

Retained Balance Growth: Expected to be within the 3%-5% range for the full year, supported by a strong pipeline in the second half of 2026.

4Bad News, Challenges, or Points of Concern

Variable Investment Income: Below expectations due to lower private equity returns, which may impact overall earnings.

Mortality Normalization: Favorable mortality trends may not persist, with expectations of normalization impacting future Group Life results.

PRT Market: The jumbo market has been lighter in the first half of 2026, raising concerns about growth in pension risk transfers.

Expense Management: While the direct expense ratio is on target, the addition of PineBridge Investments has a structurally higher expense profile.

5Notable Q&A Insights

M&A Strategy: MetLife remains disciplined regarding M&A, focusing on asset management and group segments, with no immediate gaps identified.

Group Life Pricing: Management indicated that any normalization in mortality would unfold gradually over several years, with a renewal cycle of 3-5 years.

Private Equity Position: The company is reducing its allocation to private equity, with expectations that distributions will outpace contributions moving forward.

Japan Market Dynamics: Despite market volatility, MetLife's diversified distribution and product innovation have supported strong sales growth in Japan. This summary encapsulates the key points from MetLife's Q2 2026 earnings call, highlighting both the positive performance and the challenges faced by the company.